This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novo Nordisk A/S

Drug Names(s): liraglutide, NN2211 (diabetes), NN8022 (obesity), NN9211 (adjunct), LATIN T1D (adjunct), NN9223 (depot), Saxenda (obesity)

Description: Liraglutide is an analog of glucagon-like peptide (GLP-1) with 97% of the same sequence, modified by the addition of a fatty acid group. This makes it less available to destruction by DPP-IV and enables noncovalent binding to serum albumin after injection, thereby prolonging its half-life (approximately 12 hours). The drug also forms heptamers, delaying absorption. It is given by subcutaneous injection, with a G31 (31 gauge) needle or G31 with a G32 tip.

GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.

Deal Structure: Scios and Novo Nordisk
In September 1996, Scios announced that it has granted Novo Nordisk exclusive license to Scios' insulinotropin technology. Under the terms of the agreement, Novo Nordisk will continue its Phase II clinical trial program and product development activities. The license gives Novo Nordisk exclusive worldwide rights to Scios' insulinotropin technology and patents. Scios will receive an up-front payment and time and event-based milestone payments and royalties upon commercialization. Additional terms were not disclosed.

Johnson and Johnson and Scios
In February 2003, Johnson & Johnson and Scios announced they signed a definitive agreement under which Johnson & Johnson will acquire Scios in a cash for stock exchange.

Partners: Johnson & Johnson

Victoza News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug